Raphael Pharma reports positive proof-of-concept study of cannabinoid formula in RA

Raphael Pharmaceutical Inc.

DAS28 score reduced by 19.2%, moving from high to moderate disease activity in 12 patients.
Participants in remission increased from 0% at baseline to 16.67% at week 8.
Pain levels dropped from 75% reporting negative result to 50%; morning stiffness from 75% to 41.67%.
91.7% of participants would recommend Raphael's Formula to others with RA; 83.3% willing to continue use.
Blood biomarkers showed no statistically significant changes, but overall symptom management improved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.